Original Research
Published on 06 Feb 2025
HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1449106
- 7,858 views
- 4 citations

